Skip to content

cancer

For a company of our size, we are driving our oncology division to be:

Focused

Rare cancers, mastered technologies, and specific action mechanisms.

Innovative

Open ecosystems, substantial R&D investments, and precision medicine

Three-pronged approach to our oncology strategy

  1. Target rare cancers with unmet medical needs
    Guided by patient needs, we strive to develop major therapeutic innovations in areas where needs are greatest. These include digestive cancers (stomach cancer, pancreatic cancer, and cholangiocarcinoma, a rare and aggressive form of bile duct cancer), glioma, or brain tumors, hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma), and pediatric cancers.
  2. Concentrate on promising and complementary therapeutic approaches
    At Servier, we focuse our oncology R&D programs on two promising areas:
    • Immuno-oncology – Activating the immune system to fight against cancer cells;
    • Targeted therapies – Specifically targeting one of the biological mechanisms of cancer cells.

Targeted therapies as cancer treatments

As oncology evolves toward increasingly personalized therapeutic approaches, targeted therapies make it possible to propose solutions in line with patient needs. This is especially the case for rare cancers, for which there are still too few therapeutic solutions.

  1. Draw on a wide range of expertise
    Our teams encompass a high level of expertise, which is why we encourage cross-divisional collaboration through our various research centers around the world. All our R&D centers work in a collaborative manner, pooling their remarkable expertise through cutting-edge technology platforms:
    • Our R&D center in Boston is located in the heart of one of the world’s most innovative health ecosystems ;
    • Symphogen in Denmark is our high quality monoclonal and bi-specific antibody center of excellence ;
    • Our Servier Research & Development Institute is based within the Paris-Saclay interdisciplinary innovation cluster

To step up the pace of research and development in innovative treatments, we unrelentingly promote and pursue open innovation with pharmaceutical labs, biotech companies, prestigious academic institutions, and start-ups.

In oncology, we have formed around 40 research partnerships and collaborations.

Focus

8 oncology treatments available for patients throughout the world

Learn more about our oncology development projects

By patients’ side

Digestive cancers

Understanding digestive cancers: Insight

Improving patients’ quality of life

At Servier, we work with patients at all stages of the medicine’s life cycle.

We have published a number of brochures and videos developed in collaboration with expert patients, patient representatives, carers and health care professionals. Designed for patients living with digestive cancers to support them, as well as their family, throughout their cancer journey, these materials form part of SHAPE,2 an international program launched by Servier in collaboration with Digestive Cancers Europe.

Movie about GI cancers
00:00 / 00:00
Brochures for patients

My Mood

“Looking after your emotional health for people with metastatic colorectal cancer”

Brochures for patients

MyDialogue

“Getting more from your conversations with health care professionals” – for people with metastatic colorectal cancer

Brochures for patients

MyFood

“Eating well with gastrointestinal cancer”

 

Brochures for patients

MyJourney

“Guiding you through the different stages of living with metastatic gastrointestinal cancer”

Brochures for patients

MyMove

“A Practical Guide to Moving More for people with metastatic colorectal cancer”

Brochures for patients

MyWeb

“A guide to finding trustworthy information online related to gastrointestinal (GI) cancers.”

Brain tumors

Understanding glioma

Glioma is the most common primary brain tumor in adults. While brain cancers are difficult to treat, detecting and removing the tumor as early as possible is crucial to optimizing prognosis.

Leukemia

Photo of a child with leukemia in the hospital

Understanding acute lymphoblastic leukemia

This cancer, that involves the bone marrow, affects a particular type of white blood cells, lymphoblasts (lymphocytes at an early stage of development). It is the most common leukemia in children, although it affects all age groups.

Understanding acute myeloid leukemia

Acute myeloid leukemia (AML) is a rare disease which mainly affects the elderly. It is a blood and bone marrow cancer which develops rapidly without therapeutic treatment.

Understanding myelodysplastic syndromes

Myelodysplastic syndromes (MDS) affect the bone marrow, which then produces too few healthy blood cells. MDS are difficult to qualify owing to their complexity and can evolve into acute myeloid leukemia (AML) if not detected in time.

Got a question?

Want to report a side effect?
Check out our Pharmacovigilance page.


[1] World Health Organization
[2] “Support Harmonized Advances for better Patient Experiences”